NetworkNewsAudio – Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
This audio news release has been disseminated on behalf of Quantum BioPharma and may include a paid advertisement. Related Editorial Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (Profile) is challenging that…







